InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has entered into a securities purchase agreement with two healthcare-focused institutional investors. The agreement outlines plans for the issuance and sale of 1,818,185 of INM common shares; the shares will be issued at a purchase price of $3.30 per share or prefunded warrant. In addition, the agreement notes that INM will issue unregistered preferred investment options to the same investors; those options include purchasing up to 3,272,733 additional common shares. According to the announcement, the company anticipates the private placement, which is expected to close on or about Nov. 21, 2022, could total approximately $6 million in gross proceeds. INM plans to use the funds to support the development of its pharmaceutical drug candidate as well as advance manufacturing know-how of cannabinoids and cannabinoid analogs and strengthen intellectual property development; the funding may also be used to assist with other commercial activities and general working capital purposes. H.C. Wainwright & Co. is the exclusive placement agent for the offering.
To view the full press release, visit https://cnw.fm/8jd48
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.